Pharmacogenomics falls in the branch of precision medicine and deals with the drug response in an individual based on his/her genetic profile. It hence allows doctors to devise a tailor-made prescription for patients suffering from life-threatening diseases such as cancer, neurological, and cardiovascular disorders. Furthermore, use of pharmacogenomics-based diagnostic tests facilitates improved drug response, reduced probability of drug failure, enhanced drug efficiency, and higher survival rate in case of cancer. Pharmacogenomics majorly includes the use of bioinformatics tools and several molecular biology techniques to determine the reason for an individual patient's illness at a molecular level. Furthermore, treatment is followed with the use of required dosage to address an individual patient's illness. This report takes into consideration the revenue generated by the sales of instruments, reagents, software, solutions, services, and therapeutics used to practice pharmacogenomics.

CHAPTER 1: INTRODUCTION 

CHAPTER 2: EXECUTIVE SUMMARY 

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: PHARMACOGENOMICS MARKET, BY TECHNOLOGY

CHAPTER 5: PHARMACOGENOMICS MARKET, BY APPLICATION

CHAPTER 6: PHARMACOGENOMICS MARKET, BY END USER 

CHAPTER 7: PHARMACOGENOMICS MARKET, BY REGION

CHAPTER 8: COMPANY PROFILES